一维镉(Ⅱ)配合物[Cd(H2ASA)2(H2O)2]n的合成、晶体结构及光致变色性质

以5-偶氮四唑水杨酸(H3ASA)和CdCl2·2.5H2O为原料,通过常规溶液法合成了一个镉配合物[Cd(H2ASA)2(H2O)2]n(1).通过X-射线单晶衍射、X-射线粉末衍射、元素分析、红外光谱、热重分析、紫外光谱进行结构解析和性质表征.结果 表明配合物1属于三斜晶系,Pi空间群,晶胞参数为a =0.702 39(5) nm,b=0.735 15(6) nm,c=1.229 41(7)nm,α =82.557(5)°,β=75.453(6)°,γ =61.882(8)°,V=0.541 90(8) nm3,Z=1,μ=1.083 mm-1,Dc=1.884g/cm3.配合物1中具有H2ASA-,作为μ2-桥联配体连接两个不同的Cd(Ⅱ)离子形成无限一维链结构,相邻直链通过O…O、O…N氢键和π-π堆积作用形成三维超分子框架.紫外光谱测试表明配合物1在365 nm紫外光照射下具有光致异构性质.     

{[Ln(H_2O) _2(O_2CCH_2CH_2CO_2) _3]·H_2O}_n (Ln=Eu(Ⅲ),Sm(Ⅲ)的合成、晶体结构及荧光性质

用溶剂热法合成了稀土-有机配位聚合物{[Ln(H_2O) _2(O_2CCH_2CH_2CO_2) _3]·H_2O}n (Ln=Eu(Ⅲ),Sm(Ⅲ)).采用红外光谱、X射线单晶衍射对其结构进行了表征.结果表明:两个晶体同属于单斜晶系,空间群为C2/c,含铕配位聚合物1的晶体结构参数为:a= 2.000(04) nm,b=0 .7780(02) nm,c=1.387(03) nm,α=90 °,β=121.58(3) °,γ= 90 °,V＝1.838(66) nm~3,Z＝4,F(000)=1344, M_r= 706.18, D_c= 2.551 Mg/m~3, μ=6.839 mm~(-1), R_1=0.0357, ωR_2=0.1012;含钐配位聚合物2的晶体结构参数为:a = 2.0072(02)nm,b = 0.7822(26)nm,c= 1.3901(61) nm,α = 90°,β = 121.5840°,γ = 90 °,V＝1.8593(3) nm~3,Z＝4,F(000)=1336,M_r= 70296,D_c= 2.511 Mg/m~3,μ= 6.333 mm~(-1),R_1=0.0210,ωR_2=0.0498.同时研究了它们的固体荧光性能.     

钴(Ⅱ)三元配合物[Co(pht)2(MeOH)2(H2O)2]的合成与晶体结构

利用溶剂热法合成了一个新的钴(Ⅱ)配合物[Co(pht)2(MeOH)2(H2O)2](Hpht:苯妥英,即5,5-二苯基-2,2咪唑烷酮),通过元素分析、红外光谱、热重差热分析、X射线单晶衍射等技术对其结构进行了表征.单晶结构分析表明,该晶体属单斜晶系,P21/C空间群,晶胞参数:a=1.2124(2)nm,b=1.09996(19)nm,c=1.1574(2)nm,β=92.555(2)°,V=1.5419(5)nm3,Dc=1.425 mg/m3,Z=2,F(000)=690,μ=0.615 nm-1,R1=0.0467,wR2=0.1116[I>2σ(I)],GOF=1.026.Co(Ⅱ)离子位于八面体的中心,与六个配位原子配位(40+2N).     

新型配位聚合物[Co(pda)2(H2O)2]n的水热合成和晶体结构

以CoCl2·6H2O和3-(3-吡啶基)丙烯酸(pda)为原料,在中温水热反应条件下,合成了一种新型配位聚合物[Co(pda)2(H2O)2]n单晶体,并对其进行了元素分析、红外光谱表征、TGA-GTA分析和X射线单晶衍射测定.该配位聚合物属单斜晶系,P2(1)/c空间群,晶胞参数为a=1.6958(8)nm;b=0.5466(3)nm;c=1.8034(8)nm;α=90°;β=106.209(7)°;γ=90°;Mr=391.24;V=1.6051(13)nm3;Z=4;dc=1.619g/cm3;μ=1.106mm-1;F(000)=804;R1=0.0367;wR2=0.0711.该晶体通过配位键的连接形成二维结构,又通过分子间氢键和π-π相互作用形成三维的网状结构.     

一种双核铜配合物[Cu(II)2(Paba)2(4,4'-Bipy)(H2O)2]·(ClO4)2的合成、表征及晶体结构

在水和甲醇的溶剂中合成了标题配合物[Cu(II)2(Paba)2(4,4'-Bipy)(H2O)2]·(ClO4)2 [PabaH=2-(2-吡啶甲基亚氨基)苯磺酸],通过红外光谱、元素分析、X射线单晶衍射等手段对配合物进行了表征.结果表明,该配合物晶体属于单斜晶系,空间群为P2(1)/n. 晶体学参数: a=14.559(2) nm, b=0.95984(13) nm, c=1.6038(2) nm, α=γ=90°, β=115.694(2)°, V=2.0197(5) nm3, Z=2.     

超分子化合物(C_(12)H_(10)N_4)(C_7H_6O_3)_2的合成、晶体结构及荧光性质

合成了超分子化合物(C_(12)H_(10)N_4)(C_7H_6O_3)_2,并进行了元素分析、红外光谱、紫外光谱表征和单晶X射线衍射分析.构筑单元之间通过多重氢键和π-π堆积作用的协同效应形成超分子化合物,并研究了化合物的固体荧光性能.研究表明:该晶体属于单斜晶系P2_1/c空间群,晶胞参数为:a=0.3974(1) nm,b=2.0330(2) nm,c=1.4343(1) nm, β=94.892(2)°,V=1.15440(19) nm~3,d_c=1.400 g/cm~3,Z = 2,μ= 0.102 mm~(-1),F_((000))=508,R_1=0.0359,wR_2=0.0893 [I>2σ(I)].     

之字链配合物Cu(phth)2(H2O)2的合成、表征及晶体结构

用Cu(NO3)2·3H2O和phth(邻苯二甲酸)混合反应得到了配合物Cu(phth)2(H2O)2(1).通过元素分析、红外光谱对配合物进行了表征,用X射线单晶衍射仪测定了配合物的晶体结构.配合物为单斜晶系,P2(1)/c空间群.晶胞参数a=0.83895(17)nm,b=1.4441(3)nm,c=0.70992(14)nm,β=112.14(3)°,V=0.7967(3)nm3,Z=2,Dc=1.792 g/cm3,F(000)=438.0,S=1.100,R1=0.0376,wR2=0.0998.铜原子为四配位,呈畸变正方形构型,通过邻苯二甲酸根的π-π堆积作用形成了一维之字型链,相邻的链之间靠氢键和π-π堆积作用形成三维分子结构.     

配合物[Cu(pht)2(fa)2](H2O)2的合成、晶体结构及性质研究

用醋酸铜、苯妥英(即5,5-二苯基-2,2咪唑烷酮,简称Hpht)与糠胺(2-furfurylamine,简称fa)反应,得到一种新的配合物[Cu(pht)2 (fa)2] (H2O)2,通过红外光谱、元素分析以及Ⅹ-射线单晶衍射的方法,对配合物的结构进行了表征.该晶体属三斜晶系,Pt空间群,晶胞参数:a =0.9878(2) nm,b=1.0068(2) nm,c=1.0640(3) nm,α=78.664(3)°,β=75.490(2)°,γ=72.050(3)°,Z=1,Dc=1.368 mg·m-3,R1=0.0986,ωR2 =0.2191.每个标题配合物分子中Cu(Ⅱ)离子与2个Hphi配体、2个fa配体的4个氮原子形成四方形构型,同时利用琼脂扩散法测试了配合物、苯妥英和铜盐对大肠杆菌(Escherichia Coli),金黄色葡萄球菌(Staphylococcus Aureus),枯草芽孢杆菌(Bacillus Subtilis)的抑菌活性,结果表明,它们对3种致病细菌均有一定的抑制作用.     

[Mn(H2O)6][Bi(edta)2.2H2O的合成与晶体结构

以MnCO3与多胺羧酸铋反应,合成了含铋多金属配合物[Mn(H2O)6][Bi(edta)]2.2H2O,通过元素分析和红外光谱对配合物的组成和结构进行了表征.用热重-差热手段研究了配合物的热分解过程,用x射线单晶衍射法测定了其晶体结构.[Mn(H2O)6][Bi(edta)]2·2H2O属单斜晶系,C2/c空间群,晶胞参数:a=2.37013(4)nm,b=0.87111(2)nm,c=1.61082(3)nm,β=97.273(1).,Z=4,Mr=1193.46,V=3.299.01(11)nm3,Dc=2.403g.cm-3,μ=11.123mm-1,F(000)=2284,R1=:0.0210,wR2=0.0567.大量分子间氢键将整个连接起来形成无限3-D结构.     

乙酸根桥联双核锌配合物的合成、表征及晶体结构

首次以乙酸锌、三(2-氨基乙基)胺及四氟硼酸钠为原料在甲醇介质中反应,合成得到了新颖桥联配合物{[( tren)Zn(CH3COO)Zn(tren)](BF4)3},用元素分析、红外光谱、核磁共振氢谱和热重分析对其进行了表征,用X-射线单晶衍射仪测定了其晶体结构,其晶体属于四方晶系,空间群为P-42(1)m,晶体参数分别为a=1.16106(19) nm,b=1.16106(19) nm,c=1.0851(3) nm,α=β=γ=90 °,V= 1.4627(6) nm3 ;Dc=1.686 g/cm3;Z = 3;F(000)=756;μ=1.745 mm-1.     

Synthesis and crystal structure of a terephthalato-bridged copper(II) complex [Cu2(tpt)(bpy)2(H2O)4] [Cu2(tpt)3 (bpy)2(H2O)2]

A terephthalato-bridged copper(II) complex [Cu₂(tpt)(bpy)₂(H₂O)₄][Cu₂(tpt)₃(bpy)₂ (H₂O)₂] (1) (tpt = terephthalate, bpy =; 2,2'-bipyridine) was synthesized by the reaction of Cu(ClO₄)₂ 6H₂O and terephthalic acid in the presence of 2,2'-bipyridine in H₂O solution. Crystal structure of 1 was determined by X-ray diffraction analysis in the triclinic space group P , with a = 10.7327(10) Å, b = 11.1658(11) Å, c = 17.3768(16) Å, = 108.063(2), = 91.064(2), = 116.721(2), V = 1737.5(3) ų, and Z = 2. Both the anion and the countercation in 1 are copper(II) complexes linked by terephthalate bridges in the bis(monodentate) (syn–anti) mode. The anion and the countercation are also linked by two hydrogen bonds between coordinating water molecules and terephthalate ligand.     

Synthesis and crystal structure of di(2-aminopyrimidinium) trichlorodimethyl(2-aminopyrimidine)stannate(IV) chloride (H-2APY)2[SnMe2Cl3(2APY)]Cl

The synthesis and molecular structure of di(2-aminopyrimidinium) trichlorodimethyl(2-aminopyrimidine)stannate(IV) chloride (H-2APY)₂[SnMe₂Cl₃(2APY)]Cl is reported. The compound crystallized in the orthorhombic space group Pnma with a = 20.524(1) Å, b = 10.822(1) Å, c = 10.472(1) Å and V = 2325.9(3) ų, Z = 4. The structure consists of three fragments: the hexacoordinated organotin anionic complex [SnMe₂Cl₃(2APY)]⁻, which exhibits distorted octahedral geometry; two protonated 2-aminopyrimidinium cations (H-2APY)⁺, and one chloride anion.

     

A Unique Example of a Co-crystal of [Co(AMTTO)2(H2O)2](NO3)2 and [Co(AMTTO)2(CH3CN)2](NO3)2 (AMTTO = 4-amino-5-methyl-1,2,4-triazol-3(2H)-thione)

A co-crystal of cobalt(II) complexes, Co(AMTTO)₂(CH₃CN)₂]²⁺(NO₃)₂. [Co(AMTTO)₂(H₂O)₂]²⁺(NO₃)₂, compound (1) was isolated from the reaction of Co(NO₃)₂?6H₂O and 4-amino-3-mercapto-6-methyl-5-oxo-1,2,4-triazine (AMTTO) in acetonitrile as solvent. Isolated crystals were characterized by elemental analyses, IR spectroscopy as well as X-ray diffraction studies. Crystal data for 1 at 95 K revealed a monoclinic space group P2₁/n, a?=?11.7903(5), b?=?12.1279(5), c?=?14.1443(6) Å, β?=?99.244(4)°, Z?=?2, R₁?=?0.0339. Compound 1 consists of two co-crystallized Co(II) complexes [Co(AMTTO)₂(CH₃CN)₂]²⁺ and [Co(AMTTO)₂(H₂O)₂]²⁺ and four nitrate counter anions In both complexes, cobalt(II) ions are in an octahedral arrangement. Two S, N bidentate AMTTO ligands are coordinated to both Co(II) ions. The coordination sphere of Co1 is completed by two acetonitrile molecules, and these positions are occupied by water molecules for Co2.

Graphic Abstract

A co-crystal of cobalt(II) compound was isolated from the reaction of Co(NO₃)₂?6H₂O and 4-amino-3-mercapto-6-methyl-5-oxo-1,2,4-triazine in acetonitrile as solvent.

     

Molecular structures of (tBu)Ga(S2CNnPr2)2 and (iPrO)Ga(S2CNEt2)2: An example of an unusual ligand pseudorotation

The molecular structures of (^tBu)Ga(S₂CNⁿPr₂)₂ (1) and (ⁱPrO)Ga(S₂CNEt₂)₂ (2) have been determined. The variation in the geometries observed for bis-dithiocarbamate compounds of gallium, (X)Ga(S₂CNMe₂)₂ (X=Cl, ⁱPrO, ^tBu) do not lie along the Berry pseudorotation pathway for the square-based pyramid to trigonal bipyramid geometrical transition. Instead, the structures appear to lie on an unusual ligand two-step, Texas, pseudorotation mechanism which results in a highly distorted trigonal bipyramidal geometry. Crystal data: (1) monoclinic, P2₁,/c, a = 9.786(1), b = 29.218(3), c = 9.452(1) Å, = 108.379(9)°, V = 2564.7(5) ų, and Z = 4. (2) Monoclinic, P2₁ /c, a = 10.980(3), b = 15.673(4), c = 12.461(3) Å, = 97.47(2)°, V = 2126.2(9) ų and Z = 4.     

Crystal structures of mixed compounds Cu(2)Gly(D-Ser)(L-Ser)2 and Cu(2)Gly 3(L-Ser)

-The crystal structures of mixed coordination compounds, Cu(2)Gly(D-Ser)(L-Ser)₂(I) and Cu(2)Gly ₃(L-Ser)(II), which contain the amino acid residues of glycine (Gly) and serine (Ser) in the 1: 3 and 3: 1 ratio, respectively, are studied by electron diffraction. Crystals I and II are triclinic, Z = 1, and space group P1. For I, a = 8.96(2) Å, b = 9.66(2) Å, c = 5.07(2) Å, α = β = 90°, and γ = 92.8(3)°. For II, a = 8.37(2) Å, b = 9.65(2) Å, c = 5.06(2) Å, α = β = 90°, and γ = 92.8(3)°. Compounds I and II have layered structures that are based on the CuGly(L-Ser) fragment. Structures I and II differ mainly in their interlayer spacing and configuration of the interlayer space.     

Crystal and molecular structures of 1-(2-carboxypropan-2-ylamino)-3-(1-naphthyloxy) propan-2-ol (1) (C17H21NO4) and 1-(2-carbamoyl propan-2-ylamino)-3-(1-naphthyloxy) propan-2-ol (2) (C17H22N2O3)

The crystal structures of two new-adrenergic antagonists, derivatives of propranolol containing 2-methylalanine fragment are described in this paper. The space groups and unit-cell parameters are: compound1 (C₁₇H₂₁NO₄): monoclinic, space groupP2₁/n,a=5.787(1),b=18.703(4),c=23.526(5)Å,=96.49(2)°; compound2 (C₁₇H₂₂N₂O₃): triclinic, space groupP¯1,a=8.321(1),b=10.121(1),c=10.368(1)Å,=109.49(1)°,=90.49(1)°, =103.48(1)°. The structures were solved by direct methods and refined with full matrix least-squares techniques toR indices of 0.055 and 0.049, respectively. The molecules of compound1 exist in the crystal as dual ions. The molecules of compound2 are compact and their external chain is twisted in a characteristic way (similar to that found in peptides).     

Crystal structure of [Mn2(III)(salpa)2Cl2(H2O)2] (H2salpa = 1-(salicylaldeneamino)-3-hydroxypropane)

The manganese complex, (Mn₂(III)(salpa)₂Cl₂(H₂O)₂], has been prepared and its structure determined using x-ray crystallography. The dimer is a di-₂-alkoxo complex which is a six-coordinate manganese dimer with unsupported alkoxide bridges and a rare example of a chloride- and water-containing manganese dimer. The complex crystallizes in the monoclinic space group P2₁/c with a = 9.315(5), b = 11.130(4), c = 11.637(5) Å, = 104.33(3)°, V = 1169.0(9) ų, and Z = 2. The structure comprises discrete binuclear clusters in which the metal atoms are bridged by two alkoxo oxygens of the salpa^2– ligands. The Mn—O and Mn—N distances are in good agreement with those found for other manganese(III) Schiff base complexes. The Mn—Cl and Mn—O3 distances are 2.585(2) and 2.371(2) Å, respectively, and the Mn ··· Mn distance is 3.001(1) Å. In the crystal, there are two types of hydrogen bonding between the H₂O molecule and the Cl atom with Cl ··· H(H₂O) distance of 2.33(6) (intramolecule: –1 + x, y, –1 + z) and 2.68(6) Å (intermolecule: –1 + x, 0.5–y, –0.5 + z).     

Crystal structure ofcis-diaqua bis(2,2′-bipyridyl)chromium(III) nitrate, [Cr(bipy)2(H2O)2] (NO3)3

cis-Diaquabis(2,2-bipyridyl)chromium(III) nitrate crystallizes in the mono-clinic system, space groupP2₁/c, witha=16.102(6),b=10.792(5),c=15.076(6) Å,=112.90(5)°, andZ=4. The saltlike structure was determined from X-ray crystallography and refined toR=7.5% for 3342 observed reflections. The Cr atom is octahedrally surrounded by twocis water molecules and by two chelated 2,2-bypiridyl ligands forming two nearly orthogonal planes. Selected bond distances are: Cr-O, 2.00(1) and 1.98(1) Å, Cr-N, 2.04 Å (mean).     

Crystal and molecular structures of 1-(2-methyloxycarbonylo-propan-2-ylamino)-3-(1-naphthyloxy) propan-2-ol hydrochloride (1) (C18H24NO4Cl) and 1-(2-methylcarbamoylpropan-2-ylamino)-3-(1-naphthyloxy) propan-2-ol (2) (C18H24N2O3)

The crystal structures of two new-adrenergic antagonists, derivatives of propranolol, are reported in this paper. The space groups and unit-cell parameters are: compound1 (C₁₈H₂₄NO₄Cl), monoclinic,P2₁,a=7.215(1),b=8.591(1),c=15.017(1)Å,=95.64(1)°; compound2 (C₁₈H₂₄N₂O₃), monoclinic,P2₁/c,a=10.218(3),b=21.616(5),c=8.124(2)Å,=101.28(2)°. The structures were solved with direct methods and refined by full-matrix least-squares techniques toR indices of 0.036 and 0.066, respectively. The molecule of compound1 has an extended external chain, and thus its structure is linear, whereas the molecule of compound2 is compact, and its external chain is twisted in a characteristic way, as is the case of peptides.